Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial

OBJECTIVE: The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore, we performed a 48-week placebo-con...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:PLoS One
Päätekijät: van Lelyveld, Steven F. L., Drylewicz, Julia, Krikke, Maaike, Veel, Ellen M., Otto, Sigrid A., Richter, Clemens, Soetekouw, Robin, Prins, Jan M., Brinkman, Kees, Mulder, Jan Willem, Kroon, Frank, Middel, Ananja, Symons, Jori, Wensing, Annemarie M. J., Nijhuis, Monique, Borghans, José A. M., Tesselaar, Kiki, Hoepelman, Andy I. M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Public Library of Science 2015
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4514679/
https://ncbi.nlm.nih.gov/pubmed/26208341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0132430
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia